Harbour Investments Inc. Increases Position in Johnson & Johnson $JNJ

Harbour Investments Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 93.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 56,228 shares of the company’s stock after purchasing an additional 27,216 shares during the quarter. Harbour Investments Inc.’s holdings in Johnson & Johnson were worth $11,636,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cresta Advisors Ltd. purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $26,000. Abich Financial Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $26,000. DecisionPoint Financial LLC increased its stake in shares of Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares in the last quarter. Bay Harbor Wealth Management LLC increased its stake in shares of Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after purchasing an additional 49 shares in the last quarter. Finally, Family CFO Inc purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on JNJ shares. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. TD Cowen started coverage on Johnson & Johnson in a research note on Wednesday, April 8th. They set a “buy” rating and a $250.00 price objective for the company. Daiwa Securities Group boosted their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. Guggenheim boosted their price objective on Johnson & Johnson from $244.00 to $266.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. Finally, Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a research note on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $253.04.

Johnson & Johnson Price Performance

JNJ stock opened at $234.67 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The business has a 50 day simple moving average of $233.87 and a 200-day simple moving average of $223.88. The firm has a market capitalization of $564.91 billion, a PE ratio of 27.13, a price-to-earnings-growth ratio of 2.29 and a beta of 0.27. Johnson & Johnson has a 1 year low of $149.04 and a 1 year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business’s revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.3%. Johnson & Johnson’s dividend payout ratio (DPR) is 60.12%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.